Prazotec

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prazotec

What is Prazotec?

Prazotec is a pharmaceutical medication classified as a proton pump inhibitor (PPI). Its primary function is to reduce the production of acid in the stomach. The active ingredient in Prazotec is omeprazole, a compound that works by inhibiting the enzyme system known as the gastric acid pump, located within the stomach lining.

Mechanism of Action

The medication targets the final stage of acid production. By binding to the proton pumps in the parietal cells of the stomach wall, it effectively blocks the secretion of hydrogen ions into the gastric lumen. This process leads to a significant decrease in the overall acidity of the digestive environment.

General Uses

Prazotec is utilized to manage conditions where the reduction of gastric acid is beneficial for healing or symptom management. It is commonly associated with the following applications:

  • Acid Reflux and GERD: Assisting in the management of gastroesophageal reflux disease by preventing stomach acid from irritating the esophagus.
  • Gastric and Duodenal Ulcers: Aiding in the environment necessary for the recovery of sores or erosions in the lining of the stomach or the upper part of the small intestine.
  • Zollinger-Ellison Syndrome: Managing conditions involving pathological hypersecretion, where the stomach produces excessive amounts of acid.
  • Erosive Esophagitis: Supporting the healing process of damage to the esophagus caused by chronic acid exposure.

As a systemic treatment, Prazotec provides a sustained reduction in acidity rather than the immediate, short-term neutralization offered by antacids.

What side effects are possible with Prazotec?

Possible Side Effects and Safety Information

The safety profile for Prazotec, whose active ingredient is Lansoprazole, is formally documented by regulatory authorities, classifying potential reactions by frequency and the body system affected. These classifications structure the understanding of the medicine's risk profile.

Adverse Reactions Classified by Frequency

Adverse reactions are grouped according to the expected rate of occurrence, as defined in official regulatory documents:

  • Common Reactions: These are the most frequently reported non-serious effects and include headache, dizziness, and several gastrointestinal symptoms such as diarrhea, constipation, nausea, abdominal pain, and flatulence.
  • Uncommon Reactions: These include reactions such as rash, pruritus (itching), fatigue, vomiting, and increases in specific liver enzyme levels.
  • Rare and Very Rare Reactions: Less frequently reported effects involve systems such as the metabolism and nutrition system (e.g., hyponatremia and hypomagnesemia—low sodium and magnesium levels), and the musculoskeletal system (arthralgia, myalgia). Very rare reactions include severe hypersensitivity events.

Serious Adverse Reactions and Duration-Related Safety Notes

The official labeling documents specific, clinically significant risks. These include the potential for Clostridium difficile-Associated Diarrhea and an increased risk of bone fractures of the hip, wrist, or spine. The risk of fractures and conditions such as hypomagnesemia is officially noted to be associated with long-term use, typically defined as one year or more. Other documented serious reactions include Acute Interstitial Nephritis (AIN), a type of renal hypersensitivity reaction, and certain severe cutaneous reactions. Safety information also notes that drug clearance is reduced in individuals with severe hepatic impairment, a population requiring specific safety considerations.

Overdose and Emergency Response

The official regulatory profile for Prazotec (Lansoprazole) overdose outlines the specific clinical manifestations that may occur following over-ingestion. No specific antidote is known for this medication, a factor that restricts management to supportive medical care. For any suspected over-ingestion, it is explicitly required to seek immediate medical attention and/or contact a Poison Control Center without delay.

Documented overdose cases, which include exposures up to 600 mg of Lansoprazole, indicate that severe or lethal consequences are rare. Nevertheless, the presence of specific physical signs necessitates urgent medical evaluation. Following a significant exposure, intensive hospital monitoring may be required to address potential effects.

Management protocols strictly define treatment as symptomatic and supportive. This approach is designed to manage the specific neurological, cardiovascular, and gastrointestinal signs that have been officially documented in regulatory reports. These documented effects include:

Documented Clinical Manifestations Required Emergency Actions
Lethargy, Ataxia, Dizziness Seek immediate medical attention.
Blurred Vision, Headache Contact a Poison Control Center immediately.
Nausea, Vomiting, Tachycardia Intensive monitoring may be required.

This clear regulatory framework governs the response to over-ingestion, focusing solely on the management of documented physiological effects and the mandatory professional consultation.

Therapeutic Uses of Prazotec

Quick Facts

  • Assists in the management of symptoms associated with active duodenal ulcer.
  • Aids in the resolution of active gastric ulcers.
  • Helps in the short-term treatment of erosive reflux esophagitis.
  • Contributes to the management of long-term healing for conditions like healed reflux esophagitis.
  • Is an option for the treatment of hypersecretory conditions such as Zollinger-Ellison syndrome.

Prazotec is a medication indicated to assist in the management of several conditions related to excess stomach acid production. The therapeutic domain of the drug is focused on aiding in the resolution and relief of gastrointestinal distress caused by acid.

One primary use is the short-term treatment to promote healing in individuals experiencing active gastric ulcers and duodenal ulcers. It is also an option used to support the healing process of erosive reflux esophagitis, which involves damage to the esophagus from stomach acid. For long-term needs, the drug can be utilized for the maintenance of healing in patients with healed duodenal ulcers and reflux esophagitis. Furthermore, Prazotec may be prescribed to help manage hypersecretory conditions, which are characterized by the production of large amounts of stomach acid, such as Zollinger-Ellison syndrome.

Eligibility and Restrictions for Use

Who Can and Cannot Use Prazotec?

This section outlines the official population eligibility and non-eligibility rules for Prazotec (Lansoprazole), as stated in governmental regulatory documents.


Contraindications and Absolute Restrictions

Use of Prazotec is contraindicated (absolutely prohibited) in individuals with known hypersensitivity to Lansoprazole or any component of the formulation. It is also contraindicated for patients concurrently receiving rilpivirine-containing products or nelfinavir, due to regulatory-defined concerns over reduced drug effectiveness.

Age-Group Eligibility

Population Group Eligibility Status Key Restriction
Adults (18+) Approved Standard use without specific age-related restrictions.
Pediatric Approved (1–17 years) Not recommended or avoided in infants under 1 year of age.
Geriatric Allowed A maximum daily dose of 30 mg should generally not be exceeded unless clinically justified (SmPC).

Condition-Based and Life-Stage Limitations

  • Hepatic Impairment: Use in patients with moderate or severe liver disease requires special consideration for a reduced daily dose (SmPC recommends a 50% reduction).
  • Renal Impairment: No dosage adjustment is necessary, suggesting unrestricted eligibility based on kidney function.
  • Pregnancy/Lactation: Use is not recommended during pregnancy unless clearly needed, and it is not recommended while breastfeeding (NIH LactMed).

What should I know about interactions with other medicines?

Prazotec's interaction profile is categorized by its primary effect of profound gastric acid reduction and its role as a weak inhibitor of specific metabolic enzymes, as documented in official prescribing information.

Formally Documented Restrictions and Exposure Changes

The co-administration of Prazotec with certain agents is subject to official restrictions or monitoring requirements:

  • Contraindicated Combinations: Co-administration with the antiretroviral Rilpivirine is formally contraindicated. Use with Atazanavir is officially not recommended, as the increase in gastric pH significantly reduces the plasma exposure of these agents, potentially compromising their efficacy.

  • Enzyme-Mediated Interactions (CYP): Prazotec's weak inhibition of the CYP2C19 enzyme reduces the exposure of the active metabolite of the antiplatelet agent Clopidogrel.

  • Monitoring Required: Co-administration with Warfarin may require monitoring of the International Normalized Ratio (INR). Therapeutic drug monitoring is mandated when Prazotec is used with the immunosuppressant Tacrolimus due to the potential for increased blood concentrations.

  • Other PK/PD Interactions: Prazotec is documented to reduce the absorption of drugs that require an acidic environment, such as the antifungals Ketoconazole and Itraconazole, due to the elevation of gastric pH. Conversely, the herbal product St. John’s Wort significantly decreases Prazotec's plasma exposure.

Administration Timing Constraints

The official label states that Prazotec should be administered at least 30 minutes prior to taking the anti-ulcer agent Sucralfate. This timing separation is required because Sucralfate is documented to reduce and delay Prazotec's systemic absorption.

Mechanism of Action

How Prazotec Works

Prazotec's mechanism is defined by its highly specific action against the enzyme responsible for gastric acid production, resulting in a sustained change in intragastric pH.


Acid-Dependent Activation and Target Lock-on

Prazotec operates as a chemically stable prodrug that requires a precise, low- pH environment for activation. The parent molecule is concentrated within the highly acidic secretory canaliculi of the stomach's parietal cells, where it is rapidly converted into its active sulfenamide form. This active metabolite then achieves irreversible inhibition by forming a covalent bond with specific cysteine residues on the H^+/ K^+- ATPase enzyme (the Gastric Proton Pump), locking it into an inactive state.


Sustained Suppression of Gastric Acidity

By irreversibly blocking the Proton Pump, which is the final common pathway for acid secretion, Prazotec results in a prolonged physiological consequence. This mechanism suppresses the extrusion of Hydrogen ions ( H^+) regardless of whether the stimulus is basal (fasting) or stimulated (meal-induced), resulting in a sustained elevation of the intragastric pH. The duration of this acid suppression is governed by the time required for the parietal cells to synthesize new, functional Proton Pump enzymes, which results in prolonged modulation of the gastric environment.

Dosage and Administration Information

How to Use Prazotec: Official Administration Guidelines

This section outlines the standard administration and dosing protocols for Prazotec (Lansoprazole).


Official Routes, Forms, and Timing

Prazotec is exclusively approved for oral administration. The available forms are delayed-release capsules (15 mg and 30 mg) and orally disintegrating tablets (ODTs).

Administration Element Official Instruction
Timing Relative to Meals Must be taken before eating (pre-prandial) to optimize absorption.
Capsule Handling The capsule must be swallowed whole and must not be crushed or chewed to preserve the enteric coating.
Alternative Use The intact pellets may be mixed with a small amount of specific juices (e.g., apple, orange) or soft foods (e.g., applesauce) and swallowed immediately.

Standard Dosing and Frequency

Dosage and frequency are determined by the specific condition being managed, but generally involve once-daily administration.

  • Acute Healing: The typical regimen for conditions like active gastric ulcers or erosive esophagitis is 30 mg taken once daily. Treatment courses are generally short-term, such as up to 8 weeks.
  • Maintenance: Long-term management of healed conditions often involves a lower dose of 15 mg taken once daily.
  • Hypersecretory Conditions (ZES): Initial dosing is typically 60 mg once daily. Doses exceeding 120 mg per day must be divided and administered twice daily.

Use in Specific Populations and Conditions

Standard instructions provide specific guidance for certain patient groups:

  • Hepatic Impairment: A dose adjustment, often to 15 mg once daily, is officially recommended for patients with severe liver impairment due to reduced drug clearance.
  • Older Adults & Renal Impairment: No general dosage adjustment is necessary for geriatric patients or those with kidney impairment.
  • Missed Dose: If a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Prazotec

This overview summarizes the type of research that has been conducted to evaluate Prazotec's use for its approved conditions, detailing the study designs, the outcomes that were measured, and areas where evidence is still limited or ongoing. This information is purely descriptive and does not constitute medical advice or recommendations.


Evidence from Trials for Healing Ulcers

Short-term Randomized Controlled Trials (RCTs) were the primary research method used to evaluate Prazotec's effect on duodenal ulcers and active benign gastric ulcers. Researchers primarily monitored the endoscopic healing rate (complete resolution of the lesion), alongside patient-reported outcomes describing perceived discomfort, such as pain. Findings describe patterns observed in the studies where a high proportion of patients reported measurements consistent with ulcer healing over the studied duration.

What remains uncertain is the need for more long-term data on preventing the recurrence of these ulcers following monotherapy after the initial healing phase is complete. The existing short-term studies provide limited specific insight into the factors that predict long-term ulcer freedom.


Research for Erosive Esophagitis (EE) and GERD Symptoms

  • Prazotec was studied for large-scale RCTs and placebo-controlled trials for the healing of erosive reflux esophagitis (EE).
  • Research examined temporary physiological imbalance by monitoring changes in 24-hour intra-gastric pH levels, as well as the endoscopic healing of the esophageal lining.
  • Research into the acute healing phase has explored outcomes across numerous trials, but long-term effects are not fully established for all patient groups.

Studies on Maintenance, Prevention, and Long-Term Use

To assess the drug's role in the long-term management of acid-related conditions, Prazotec was studied for evaluating disease recurrence following the healing of erosive esophagitis. Long-term RCTs, spanning up to a year, were conducted, with the primary outcome being the prevention of disease relapse or recurrence, which was confirmed by follow-up endoscopy.

Research describes patterns observed in the studies related to outcomes monitoring physiological strain or stress, but limited information for long-term outcomes extending past the typical 12-month trial period is a key research limitation.

Frequently Asked Questions (FAQ)

Common questions about Prazotec (FAQ)


Q: How quickly does Prazotec usually start to work?

A: Official studies indicate that the effect of Prazotec on gastric acid levels may begin within one to two hours after the first dose. The concentration of the medicine in the blood plasma reaches its peak in approximately 1.7 hours. This process is the mechanism by which the sustained suppression of acid secretion is initiated.

Q: What is the longest period someone typically takes Prazotec for?

A: Prazotec is approved for use in both short-term acute treatment, such as for the healing of ulcers over approximately eight weeks, and for long-term chronic maintenance therapy. The purpose of long-term use is typically to reduce the recurrence of healed conditions, and regulatory documents include information for use over multiple months.

Q: Can Prazotec cause sleep issues or insomnia?

A: The official regulatory documents classify insomnia (difficulty sleeping) as a rare adverse reaction. A rare classification indicates this effect is reported with a very low frequency. Official safety information details all reported adverse reactions by their expected frequency.

Q: Does Prazotec affect blood pressure?

A: The official safety profile does not list changes in blood pressure among the common or uncommon reactions. However, severe allergic reactions, which are rare and highly uncommon, are described as sometimes being accompanied by a fall in blood pressure.

Q: Does Prazotec make people feel drowsy?

A: Official safety documents list dizziness as a common reaction and fatigue (a general feeling of tiredness) as an uncommon reaction. These effects are related to the central nervous system, but drowsiness itself is not listed as a frequent side effect in the official safety profile.

Q: How does Prazotec work in simple terms?

A: Prazotec works by targeting the stomach’s Proton Pump, which is the final step in the process of gastric acid secretion. The medicine is converted into an active form that irreversibly blocks this pump, leading to sustained suppression of acid secretion. This mechanism results in a consistent reduction of gastric acidity.

Q: What does the research say about long-term use of Prazotec?

A: Research has examined the drug's role in the long-term prevention of disease recurrence in trials lasting up to one year. Official safety information specifically notes that long-term use (typically defined as one year or more) is associated with an increased risk of conditions like bone fractures and low magnesium levels (hypomagnesemia). Findings describe patterns observed in the studies related to outcomes monitoring physiological strain.

Q: Does Prazotec have a risk of dependence or withdrawal symptoms?

A: Official documentation does not describe physical dependence on Prazotec. However, it does mention that stopping the medicine following prolonged treatment may lead to rebound acid hypersecretion. This phenomenon describes a temporary increase in acid production above pretreatment levels.

Q: Is Prazotec studied for use in children?

A: Official regulatory bodies have approved Prazotec for use in pediatric patients between 1 and 17 years of age. Studies have been conducted to evaluate the safety and effectiveness of the medicine within this specific population. Use in infants under 1 year of age is generally not recommended.

Q: Does the efficacy of Prazotec change over time?

A: Regulatory information addresses the duration of the acid-suppressing effect. It notes that after multiple doses are stopped, the inhibition of acid secretion gradually returns to normal over a period of two to four days. This time frame is related to the natural synthesis of new acid pumps by the body.

Q: Are there any specific vitamins or supplements that interact with Prazotec?

A: The official product information specifies an interaction with the herbal product St. John’s Wort. This interaction is described as significantly decreasing the concentration of Prazotec in the blood, which could compromise its effectiveness. The official guidance advises patients to discuss all supplements and vitamins with a healthcare provider.

Q: What happens if a dose of Prazotec is missed?

A: Official instructions state that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Official instructions specify that two doses must not be taken together to make up for a missed dose.

Q: Does Prazotec need to be taken at the exact same time every day?

A: Official instructions require Prazotec to be administered once daily and specifically before eating (pre-prandial) to ensure optimal absorption. While consistency is often helpful for any daily medication, the regulatory label primarily emphasizes the relationship to food for effective use.

Q: What is the half-life of Prazotec, approximately?

A: The half-life is a scientific concept measuring the time it takes for half of the medicine to be eliminated from the bloodstream. In healthy individuals, the mean plasma elimination half-life of the active ingredient is approximately 1.5 hours.

Q: Can Prazotec cause headaches?

A: Headaches are one of the most frequently reported non-serious side effects. The official safety profile lists headache as a common adverse reaction. All adverse reactions are classified by frequency in official documents to structure the understanding of the medicine's risk profile.

Q: Are there common foods or drinks to avoid while taking Prazotec?

A: Official administration guidance states that the medicine must be taken before eating to optimize absorption of the active ingredient. Additionally, the drug pellets inside the capsule may be mixed with specific soft foods or juices, such as applesauce, as defined in the official label. The guidance for administration is based on regulatory documents.

Q: Why is Prazotec sometimes taken in the evening?

A: Prazotec is generally taken once daily. For patients with certain severe hypersecretory conditions where high doses are needed, the official guidance requires the total daily dose to be divided and administered twice daily. This required administration schedule would necessitate an evening dose.

Q: Can Prazotec be cut in half or crushed?

A: The delayed-release capsules are designed with a special coating to protect the medicine from stomach acid. Official guidance indicates that the capsule must be swallowed whole and must not be crushed or chewed to maintain the integrity of the protective coating.

Q: Can Prazotec be taken with antacids?

A: Official information indicates that common antacids may be used concomitantly, meaning at the same time, if needed for temporary pain relief. Antacids are not contraindicated when taking Prazotec.

Q: Is Prazotec a controlled substance?

A: Prazotec is chemically classified as a Proton Pump Inhibitor (PPI) and is used as an anti-ulcer agent. Based on its classification and mechanism of action, it is not listed as a controlled substance by government agencies.

Q: Does Prazotec interact with birth control pills?

A: Studies have been conducted to evaluate potential drug interactions with hormonal contraceptives. Official information indicates that Prazotec does not generally affect the bioavailability (how much medicine enters the circulation) of oral contraceptives.

Q: Is Prazotec used for acute or chronic conditions?

A: It is officially approved for managing both short-term acute conditions, such as the healing of active ulcers or erosive esophagitis. It is also approved for long-term maintenance therapy to prevent the recurrence of these conditions after the initial healing phase is complete.

How should Prazotec be stored and disposed of?

How to Store and Dispose of Prazotec?

The official labeling for Prazotec (lansoprazole) defines specific conditions necessary to maintain its stability and effectiveness.

Requirement Storage Detail
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Brief excursions are permitted between 15 C and 30 C.
Protection Protect from moisture and keep out of high heat and humidity.
Container Must be kept in the original container with the cap closed tightly after each use.
Child Safety Keep the medication out of reach of children.

Disposal instructions require the product to be discarded following proper drug disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prazotec found in:

A-Z Index: